Relationship between bone mineral density and ovarian function and thyroid function in perimenopausal women with endometriosis: a prospective study

Table 1 Baseline characteristics of participants

	N	Mean
Age (years)	207	45.02 ± 2.73
Weight (kg)	207	55.31 ± 9.02
Height (cm)	207	159.23 ± 5.67
Body mass index (kg/m²)	207	21.80 ± 3.27
Systolic blood pressure (mmHg)	198	121.98 ± 13.04
Diastolic blood pressure (mmHg)	198	78.98 ± 10.29
FSH (mIU/mL)	202	33.42 ± 41.84
E₂ (pg/mL)	201	92.98 ± 107.48
TSH (μIU/mL)	198	1.72 ± 1.11
Free T₄ (μg/dL)	199	1.09 ± 0.17
AMH (ng/mL)	166	0.36 ± 0.57
TRACP-5b (mU/dL)	174	242.42 ± 111.96
BMD (g/cm²)	207	1.16 ± 0.15
Current hormonal therapy (%)	106	51.21
Surgical treatment (%)	171	82.61
Residual ovary
Bilateral (%)	129	62.32
Unilateral (%)	73	35.27
None (%)	5	2.42
Postmenopausal (%)	70	33.82
Age at menopause (years)		46.84 ± 3.33

Data were presented as means ± standard deviation or number of cases (%)
Current hormonal therapy is defined as the administration of hormonal agents within 1 year before the initial measurement
BMD was measured at the lumbar spine using dual-energy X-ray absorptiometry (DXA)
BMD, bone mineral density; FSH, follicle-stimulating hormone; AMH, anti-Müllerian hormone; TSH, thyroid-stimulating hormone; E₂, oestradiol; T₄, thyroxine; TRACP-5b, tartrate-resistant acid phosphatase-5b

ISSN: 1472-6874